Therapeutic Asset Ratings

3,848 results matching 1 filter

133,990 assets · 8,802 sponsors · 3,128 indications

Methodology v0.2

Asset	Sponsor	Phase	Rating
Axicabtagene Ciloleucel Recurrent Transformed Follicular Lymphoma to Diffuse Large B-Cell Lymphoma	Ruijin Hospital	P4	BBB (77)
Axicabtagene Ciloleucel B-cell Lymphoma Recurrent	Lyell Immunopharma, Inc.	P4	BBB (76)
Axicabtagene Ciloleucel Diffuse Large B-Cell Lymphoma, Not Otherwise Specified	Ruijin Hospital	P4	BBB (75)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs ALL	Fred Hutchinson Cancer Center	P2/3	BBB (74)
Jwcar029 Relapsed or Refractory B-cell Lymphoma	Ruijin Hospital	P4	BBB (72)
cd19-ucart B-Cell Acute Lymphoblastic Leukemia, Adult	The General Hospital of Western Theater Command	P2	BBB (72)
TIL Melanoma (Skin)	City of Hope Medical Center	P2	BBB (72)
cd19-ucart Lymphoma, B-Cell	Union Hospital, Tongji Medical College, Huazhong University of Science and Technology	P4	BB (71)
Axicabtagene Ciloleucel Primary Mediastinal (Thymic) Large B-Cell Lymphoma	AIDS Malignancy Consortium	P2	BB (71)
Axicabtagene Ciloleucel Refractory High Grade B-Cell Lymphoma	AIDS Malignancy Consortium	P2	BB (71)
Chimeric Antigen Receptor Modified T Cells Infusion B Cell Lymphoma	The First Affiliated Hospital of Soochow University	P2/3	BB (71)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription Hematologic Diseases	Vertex Pharmaceuticals Incorporated	P3	BB (70)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Acute Myelogenous Leukemia	Fred Hutchinson Cancer Center	P2/3	BB (70)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription Genetic Diseases, Inborn	Vertex Pharmaceuticals Incorporated	P3	BB (69)
Axicabtagene Ciloleucel High Grade B-Cell Lymphoma	AIDS Malignancy Consortium	P2	BB (69)
TIL Metastatic Melanoma	East Metropolitan Health Service, Australia	P2	BB (69)
Axicabtagene Ciloleucel Large B-cell Lymphoma	Zhejiang Cancer Hospital	P4	BB (68)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription Beta-Thalassemia	Daniel Bauer	P3	BB (68)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription Hemoglobinopathies	Vertex Pharmaceuticals Incorporated	P3	BB (68)
Cart-19 And 20 Cells B Cell Lymphoma	Henan Cancer Hospital	P2	BB (68)
cd22 car-transduced t cells B-All	National Cancer Institute (NCI)	P2	BB (68)
Sipuleucel-T Metastatic Prostate Cancer	Yale University	P2	BB (68)
Allogeneic Cd34+-Enriched And Cd45Ra-Depleted Pbscs Myelodysplastic Syndromes	Fred Hutchinson Cancer Center	P2/3	BB (68)
Axicabtagene Ciloleucel Lymphoma, B-Cell	Lyell Immunopharma, Inc.	P4	BB (67)
Autologous CD34+ cells isolated from mobilised peripheral blood by positive selection, modified by CRISPR/Cas9 (clustered regularly interspaced short palindromic repeats/CRISPR-associated protein 9) mediated gene editing consisting of a guide RNA (gRNA) introduced transiently as ribonucleoprotein (RNP) complex, targeting the erythroid lineage-specific enhancer region of BCL11A (B-cell lymphoma/leukemia 11A). The site-specific cleavage by Cas9 forms a double strand break (DSB), which is subsequently repaired by nonhomologous end-joining (NHEJ), leading to the transcriptional repression of BCL11A, a repressor of ?-globin gene transcription Thalassemia	Vertex Pharmaceuticals Incorporated	P3	BB (67)

Showing 1 to 25 of 3,848 assets

PreviousPage 1 of 154Next